Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Rated “Moderate Buy” by Wall Street Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company.

A number of equities research analysts have issued reports on BIOVF shares. HC Wainwright reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Wednesday. Pareto Securities upgraded shares of Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a research report on Tuesday. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, July 21st. Finally, Nordea Equity Research lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, October 22nd.

Swedish Orphan Biovitrum Price Performance

Shares of OTCMKTS BIOVF opened at $45.72 on Friday. The stock has a market capitalization of $16.27 billion, a P/E ratio of 22.74 and a beta of 0.47. The stock’s fifty day moving average is $46.06 and its 200 day moving average is $44.21. Swedish Orphan Biovitrum has a 52 week low of $34.88 and a 52 week high of $49.03. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.